ArticleProstate cancer and prostatic diseases2021

The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.

Matteo Bauckneht et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.